DNA repair pathways in human multiple myeloma

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564 - 9; http://dx.doi.org/10.1056/NEJMoa01133202; PMID: 11856795
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113:5412 - 7; http://dx.doi.org/10.1182/blood-2008-12-194241; PMID: 19179464
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8:479 - 91; http://dx.doi.org/10.1038/nrclinonc.2011.63; PMID: 21522124
   PubMed Web of Science ®Google Scholar
• Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113:5418 - 22; http://dx.doi.org/10.1182/blood-2008-12-195008; PMID: 19234139
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013; 27:1738 - 44; http://dx.doi.org/10.1038/leu.2013.86; PMID: 23515097
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362 - 9; http://dx.doi.org/10.1056/NEJMoa054494; PMID: 16571879
   PubMed Web of Science ®Google Scholar
• Zojer N, Ludwig H, Fiegl M, Stevenson FK, Sahota SS. Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma. Blood 2003; 101:4137 - 9; http://dx.doi.org/10.1182/blood-2002-09-2825; PMID: 12531815
   PubMed Web of Science ®Google Scholar
• Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999; 104:131 - 7; http://dx.doi.org/10.1046/j.1365-2141.1999.01136.x; PMID: 10027725
   PubMed Web of Science ®Google Scholar
• Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr., Barlogie B, Zhou Y, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011; 96:87 - 95; http://dx.doi.org/10.3324/haematol.2010.030296; PMID: 20884712
   PubMed Web of Science ®Google Scholar
• Greipp PR, Katzmann JA, O’Fallon WM, Kyle RA. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72:219 - 23; PMID: 3291982
   PubMed Web of Science ®Google Scholar
• Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Van Ness B, Kyle RA. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91:2501 - 7; PMID: 9516151
   PubMed Web of Science ®Google Scholar
• Paiva B, Vídriales M-B, Montalbán M-Á, Pérez JJ, Gutiérrez NC, Rosiñol L, Martínez-López J, Mateos MV, Cordón L, Oriol A, et al. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials. Am J Pathol 2012; 181:1870 - 8; http://dx.doi.org/10.1016/j.ajpath.2012.07.020; PMID: 22974582
   PubMed Web of Science ®Google Scholar
• Nussenzweig A, Nussenzweig MC. Origin of chromosomal translocations in lymphoid cancer. Cell 2010; 141:27 - 38; http://dx.doi.org/10.1016/j.cell.2010.03.016; PMID: 20371343
   PubMed Web of Science ®Google Scholar
• Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64:1546 - 58; http://dx.doi.org/10.1158/0008-5472.CAN-03-2876; PMID: 14989251
   PubMedGoogle Scholar
• Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119:2100 - 5; http://dx.doi.org/10.1182/blood-2011-11-390658; PMID: 22234687
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12:335 - 48; http://dx.doi.org/10.1038/nrc3257; PMID: 22495321
   PubMed Web of Science ®Google Scholar
• Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 2010; 79:181 - 211; http://dx.doi.org/10.1146/annurev.biochem.052308.093131; PMID: 20192759
   PubMed Web of Science ®Google Scholar
• Wilson PC, de Bouteiller O, Liu YJ, Potter K, Banchereau J, Capra JD, Pascual V. Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes. J Exp Med 1998; 187:59 - 70; http://dx.doi.org/10.1084/jem.187.1.59; PMID: 9419211
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122:3456 - 63; http://dx.doi.org/10.1172/JCI61188; PMID: 23023717
   PubMed Web of Science ®Google Scholar
• Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007; 20:571 - 96; http://dx.doi.org/10.1016/j.beha.2007.08.004; PMID: 18070707
   PubMed Web of Science ®Google Scholar
• Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5:191 - 9; http://dx.doi.org/10.1016/S1535-6108(04)00019-4; PMID: 14998494
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007; 139:730 - 43; http://dx.doi.org/10.1111/j.1365-2141.2007.06873.x; PMID: 18021088
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr.. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106:296 - 303; http://dx.doi.org/10.1182/blood-2005-01-0034; PMID: 15755896
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL. Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program 2011; 2011:344 - 53; http://dx.doi.org/10.1182/asheducation-2011.1.344; PMID: 22160056
   PubMed Web of Science ®Google Scholar
• Rio-Machin A, Ferreira BI, Henry T, Gómez-López G, Agirre X, Alvarez S, Rodriguez-Perales S, Prosper F, Calasanz MJ, Martínez J, et al. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia 2013; 27:925 - 31; http://dx.doi.org/10.1038/leu.2012.302; PMID: 23174883
   PubMed Web of Science ®Google Scholar
• Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O, Wang M, Soutoglou E, Knudsen ES, Pestell RG. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res 2010; 70:8802 - 11; http://dx.doi.org/10.1158/0008-5472.CAN-10-0312; PMID: 20940395
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122:3456 - 63; http://dx.doi.org/10.1172/JCI61188; PMID: 23023717
   PubMed Web of Science ®Google Scholar
• Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell 1999; 3:119 - 23; http://dx.doi.org/10.1016/S1097-2765(00)80180-X; PMID: 10024885
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H. Genomics in multiple myeloma. Clin Cancer Res 2011; 17:1234 - 42; http://dx.doi.org/10.1158/1078-0432.CCR-10-1843; PMID: 21411439
   PubMed Web of Science ®Google Scholar
• Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, Kyle RA, Henderson KJ, Van Wier S, Greipp P, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008; 22:2280 - 4; http://dx.doi.org/10.1038/leu.2008.142; PMID: 18528420
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012; 30:1949 - 52; http://dx.doi.org/10.1200/JCO.2011.36.5726; PMID: 22547600
   PubMed Web of Science ®Google Scholar
• Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010; 95:1973 - 6; http://dx.doi.org/10.3324/haematol.2010.023697; PMID: 20634494
   PubMed Web of Science ®Google Scholar
• Pichiorri F, Suh S-S, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr., Hofmainster C, Alder H, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18:367 - 81; http://dx.doi.org/10.1016/j.ccr.2010.09.005; PMID: 20951946
   PubMed Web of Science ®Google Scholar
• Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103:3175 - 84; http://dx.doi.org/10.1182/blood-2003-06-2151; PMID: 15070700
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115 - 30; http://dx.doi.org/10.1016/j.ccr.2007.07.004; PMID: 17692804
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng W-J, Van Wier S, Tiedemann R, Shi CX, Sebag M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12:131 - 44; http://dx.doi.org/10.1016/j.ccr.2007.07.003; PMID: 17692805
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 2008; 6:1356 - 64; http://dx.doi.org/10.1158/1541-7786.MCR-08-0108; PMID: 18708367
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467 - 72; http://dx.doi.org/10.1038/nature09837; PMID: 21430775
   PubMed Web of Science ®Google Scholar
• Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010; 115:3541 - 52; http://dx.doi.org/10.1182/blood-2009-09-243535; PMID: 20053756
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R, Intergroupe Francophone du Myélome. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001; 98:3082 - 6; http://dx.doi.org/10.1182/blood.V98.10.3082; PMID: 11698294
   PubMed Web of Science ®Google Scholar
• Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25:1026 - 35; http://dx.doi.org/10.1038/leu.2011.53; PMID: 21468039
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Affer M, Glebov OK, Chen W-DD, Keats JJ, Brents LA, et al. Promiscuous cryptic rearrangements of the MYC locus cis-dysregulate MYC expression and are present in the majority of patients with hyperdiploid myeloma. Blood ASH meeting abstracts 2012; 120:724
   Google Scholar
• Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008; 2008:25 - 31; http://dx.doi.org/10.1093/jncimonographs/lgn011; PMID: 18647998
   PubMedGoogle Scholar
• Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120:1067 - 76; http://dx.doi.org/10.1182/blood-2012-01-405985; PMID: 22498740
   PubMed Web of Science ®Google Scholar
• Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O, Godmer P, Garderet L, Voillat L, Facon T, Stoppa AM, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013; 27:473 - 81; http://dx.doi.org/10.1038/leu.2012.226; PMID: 22874878
   PubMed Web of Science ®Google Scholar
• Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R, Phillips L, Baker A, Shi CX, Schmidt J, et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol 2013; 161:748 - 51; http://dx.doi.org/10.1111/bjh.12291; PMID: 23480694
   PubMed Web of Science ®Google Scholar
• Weston-Bell N, Gibson J, John M, Ennis S, Pfeifer S, Cezard T, Ludwig H, Collins A, Zojer N, Sahota SS. Exome sequencing in tracking clonal evolution in multiple myeloma following therapy. Leukemia 2013; 27:1188 - 91; http://dx.doi.org/10.1038/leu.2012.287; PMID: 23147253
   PubMed Web of Science ®Google Scholar
• Walker BA, Morgan GJ. Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma. Clin Lymphoma Myeloma 2006; 7:186 - 91; http://dx.doi.org/10.3816/CLM.2006.n.057; PMID: 17229333
   PubMedGoogle Scholar
• Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 2013; 45:522 - 5; http://dx.doi.org/10.1038/ng.2583; PMID: 23502783
   PubMed Web of Science ®Google Scholar
• Ricke RM, van Deursen JM. Aneuploidy in health, disease, and aging. J Cell Biol 2013; 201:11 - 21; http://dx.doi.org/10.1083/jcb.201301061; PMID: 23547028
   PubMed Web of Science ®Google Scholar
• Siegel JJ, Amon A. New insights into the troubles of aneuploidy. Annu Rev Cell Dev Biol 2012; 28:189 - 214; http://dx.doi.org/10.1146/annurev-cellbio-101011-155807; PMID: 22804579
   PubMed Web of Science ®Google Scholar
• Chng WJ, Fonseca R. Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen 2009; 50:697 - 707; http://dx.doi.org/10.1002/em.20528; PMID: 19739237
   PubMed Web of Science ®Google Scholar
• Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, Dogan A, Fonseca R. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008; 111:1603 - 9; http://dx.doi.org/10.1182/blood-2007-06-097774; PMID: 18006703
   PubMed Web of Science ®Google Scholar
• Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993; 362:709 - 15; http://dx.doi.org/10.1038/362709a0; PMID: 8469282
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JHJ. DNA damage, aging, and cancer. N Engl J Med 2009; 361:1475 - 85; http://dx.doi.org/10.1056/NEJMra0804615; PMID: 19812404
   PubMed Web of Science ®Google Scholar
• Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, Osieka R. DNA methylation changes in multiple myeloma. Leukemia 2004; 18:1687 - 92; http://dx.doi.org/10.1038/sj.leu.2403434; PMID: 15318245
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011; 117:553 - 62; http://dx.doi.org/10.1182/blood-2010-04-279539; PMID: 20944071
   PubMed Web of Science ®Google Scholar
• Amodio N, Leotta M, Bellizzi D, Di Martino MT, D’Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012; 3:1246 - 58; PMID: 23100393
   PubMed Web of Science ®Google Scholar
• Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40:179 - 204; http://dx.doi.org/10.1016/j.molcel.2010.09.019; PMID: 20965415
   PubMed Web of Science ®Google Scholar
• Iyama T, Wilson DM 3rd. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst) 2013; 12:620 - 36; http://dx.doi.org/10.1016/j.dnarep.2013.04.015; PMID: 23684800
   PubMed Web of Science ®Google Scholar
• Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet 2008; 9:619 - 31; PMID: 18626472
   PubMed Web of Science ®Google Scholar
• Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1:22 - 33; http://dx.doi.org/10.1038/35094000; PMID: 11900249
   PubMed Web of Science ®Google Scholar
• Hanawalt PC, Spivak G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat Rev Mol Cell Biol 2008; 9:958 - 70; http://dx.doi.org/10.1038/nrm2549; PMID: 19023283
   PubMed Web of Science ®Google Scholar
• Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006; 7:335 - 46; http://dx.doi.org/10.1038/nrm1907; PMID: 16612326
   PubMed Web of Science ®Google Scholar
• Shaheen M, Allen C, Nickoloff JA, Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 2011; 117:6074 - 82; http://dx.doi.org/10.1182/blood-2011-01-313734; PMID: 21441464
   PubMed Web of Science ®Google Scholar
• Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011; 11:467 - 80; http://dx.doi.org/10.1038/nrc3088; PMID: 21701511
   PubMed Web of Science ®Google Scholar
• Bunting SF, Callén E, Wong N, Chen H-T, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141:243 - 54; http://dx.doi.org/10.1016/j.cell.2010.03.012; PMID: 20362325
   PubMed Web of Science ®Google Scholar
• Chapman JR, Taylor MRG, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 2012; 47:497 - 510; http://dx.doi.org/10.1016/j.molcel.2012.07.029; PMID: 22920291
   PubMed Web of Science ®Google Scholar
• Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, Bergsagel PL, Wang L, You Z, Lou Z. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011; 470:124 - 8; http://dx.doi.org/10.1038/nature09658; PMID: 21293379
   PubMed Web of Science ®Google Scholar
• Tang J, Cho NW, Cui G, Manion EM, Shanbhag NM, Botuyan MV, Mer G, Greenberg RA. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol 2013; 20:317 - 25; http://dx.doi.org/10.1038/nsmb.2499; PMID: 23377543
   PubMed Web of Science ®Google Scholar
• Hochegger H, Dejsuphong D, Fukushima T, Morrison C, Sonoda E, Schreiber V, Zhao GY, Saberi A, Masutani M, Adachi N, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 2006; 25:1305 - 14; http://dx.doi.org/10.1038/sj.emboj.7601015; PMID: 16498404
   PubMed Web of Science ®Google Scholar
• Adamo A, Collis SJ, Adelman CA, Silva N, Horejsi Z, Ward JD, Martinez-Perez E, Boulton SJ, La Volpe A. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol Cell 2010; 39:25 - 35; http://dx.doi.org/10.1016/j.molcel.2010.06.026; PMID: 20598602
   PubMed Web of Science ®Google Scholar
• Pace P, Mosedale G, Hodskinson MR, Rosado IV, Sivasubramaniam M, Patel KJ. Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Science 2010; 329:219 - 23; http://dx.doi.org/10.1126/science.1192277; PMID: 20538911
   PubMed Web of Science ®Google Scholar
• Lieber MR. NHEJ and its backup pathways in chromosomal translocations. Nat Struct Mol Biol 2010; 17:393 - 5; http://dx.doi.org/10.1038/nsmb0410-393; PMID: 20368722
   PubMed Web of Science ®Google Scholar
• West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003; 4:435 - 45; http://dx.doi.org/10.1038/nrm1127; PMID: 12778123
   PubMed Web of Science ®Google Scholar
• Hartlerode AJ, Scully R. Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J 2009; 423:157 - 68; http://dx.doi.org/10.1042/BJ20090942; PMID: 19772495
   PubMed Web of Science ®Google Scholar
• Bothmer A, Robbiani DF, Feldhahn N, Gazumyan A, Nussenzweig A, Nussenzweig MC. 53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination. J Exp Med 2010; 207:855 - 65; http://dx.doi.org/10.1084/jem.20100244; PMID: 20368578
   PubMed Web of Science ®Google Scholar
• Williams HL, Gottesman ME, Gautier J. Replication-independent repair of DNA interstrand crosslinks. Mol Cell 2012; 47:140 - 7; PMID: 22658724
   PubMed Web of Science ®Google Scholar
• Wang Y, Leung JW, Jiang Y, Lowery MG, Do H, Vasquez KM, Chen J, Wang W, Li L. FANCM and FAAP24 maintain genome stability via cooperative as well as unique functions. Mol Cell 2013; 49:997 - 1009; http://dx.doi.org/10.1016/j.molcel.2012.12.010; PMID: 23333308
   PubMed Web of Science ®Google Scholar
• Kim N, Jinks-Robertson S. Transcription as a source of genome instability. Nat Rev Genet 2012; 13:204 - 14; PMID: 22330764
   PubMed Web of Science ®Google Scholar
• Knipscheer P, Räschle M, Smogorzewska A, Enoiu M, Ho TV, Schärer OD, Elledge SJ, Walter JC. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 2009; 326:1698 - 701; http://dx.doi.org/10.1126/science.1182372; PMID: 19965384
   PubMed Web of Science ®Google Scholar
• Constantinou A. Rescue of replication failure by Fanconi anaemia proteins. Chromosoma 2012; 121:21 - 36; http://dx.doi.org/10.1007/s00412-011-0349-2; PMID: 22057367
   PubMed Web of Science ®Google Scholar
• Hayden PJ, Tewari P, Morris DW, Staines A, Crowley D, Nieters A, Becker N, de Sanjosé S, Foretova L, Maynadié M, et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol Genet 2007; 16:3117 - 27; http://dx.doi.org/10.1093/hmg/ddm273; PMID: 17901044
   PubMed Web of Science ®Google Scholar
• Roddam PL, Rollinson S, O’Driscoll M, Jeggo PA, Jack A, Morgan GJ. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet 2002; 39:900 - 5; http://dx.doi.org/10.1136/jmg.39.12.900; PMID: 12471202
   PubMed Web of Science ®Google Scholar
• Roddam PL, Allan JM, Dring AM, Worrillow LJ, Davies FE, Morgan GJ. Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma. Br J Haematol 2010; 149:258 - 62; http://dx.doi.org/10.1111/j.1365-2141.2010.08088.x; PMID: 20148879
   PubMed Web of Science ®Google Scholar
• Calimeri T, Fulcineti M, Lin J, Samur MK, Calkins AS, Vahia AV, et al. Aberrant non-homologous end joining in multiple myeloma: a role in genomic instability and as a potential prognostic marker. Blood ASH meeting abstracts 2012; 120:2932
   PubMed Web of Science ®Google Scholar
• Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Podar K, et al. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol 2000; 165:6347 - 55; PMID: 11086072
   PubMed Web of Science ®Google Scholar
• Kato M, Iida S, Komatsu H, Ueda R. Lack of Ku80 alteration in multiple myeloma. Jpn J Cancer Res 2002; 93:359 - 62; http://dx.doi.org/10.1111/j.1349-7006.2002.tb01264.x; PMID: 11985783
   PubMedGoogle Scholar
• Han Z, Johnston C, Reeves WH, Carter T, Wyche JH, Hendrickson EA. Characterization of a Ku86 variant protein that results in altered DNA binding and diminished DNA-dependent protein kinase activity. J Biol Chem 1996; 271:14098 - 104; http://dx.doi.org/10.1074/jbc.271.24.14098; PMID: 8662896
   PubMed Web of Science ®Google Scholar
• Łanuszewska J, Widłak P. The truncation of Ku86 in human lymphocytes. Cancer Lett 2004; 205:197 - 205; http://dx.doi.org/10.1016/j.canlet.2003.10.016; PMID: 15036652
   PubMed Web of Science ®Google Scholar
• Gullo CA, Ge F, Cow G, Teoh G. Ku86 exists as both a full-length and a protease-sensitive natural variant in multiple myeloma cells. Cancer Cell Int 2008; 8:4; http://dx.doi.org/10.1186/1475-2867-8-4; PMID: 18442416
   PubMed Web of Science ®Google Scholar
• Yang C, Betti C, Singh S, Toor A, Vaughan A. Impaired NHEJ function in multiple myeloma. Mutat Res 2009; 660:66 - 73; http://dx.doi.org/10.1016/j.mrfmmm.2008.10.019; PMID: 19028508
   PubMed Web of Science ®Google Scholar
• Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006; 47:2289 - 300; http://dx.doi.org/10.1080/10428190600822128; PMID: 17107900
   PubMed Web of Science ®Google Scholar
• Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 2009; 113:2290 - 7; http://dx.doi.org/10.1182/blood-2007-05-089193; PMID: 19050310
   PubMed Web of Science ®Google Scholar
• Mah L-J, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010; 24:679 - 86; http://dx.doi.org/10.1038/leu.2010.6; PMID: 20130602
   PubMed Web of Science ®Google Scholar
• Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF. Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia 2011; 25:1344 - 53; http://dx.doi.org/10.1038/leu.2011.94; PMID: 21566653
   PubMed Web of Science ®Google Scholar
• Volcic M, Karl S, Baumann B, Salles D, Daniel P, Fulda S, Wiesmüller L. NF-κB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes. Nucleic Acids Res 2012; 40:181 - 95; http://dx.doi.org/10.1093/nar/gkr687; PMID: 21908405
   PubMed Web of Science ®Google Scholar
• Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ 2006; 13:773 - 84; http://dx.doi.org/10.1038/sj.cdd.4401843; PMID: 16410802
   PubMed Web of Science ®Google Scholar
• Miyamoto S. Nuclear initiated NF-κB signaling: NEMO and ATM take center stage. Cell Res 2011; 21:116 - 30; http://dx.doi.org/10.1038/cr.2010.179; PMID: 21187855
   PubMed Web of Science ®Google Scholar
• Habraken Y, Piette J. NF-kappaB activation by double-strand breaks. Biochem Pharmacol 2006; 72:1132 - 41; http://dx.doi.org/10.1016/j.bcp.2006.07.015; PMID: 16965765
   PubMed Web of Science ®Google Scholar
• Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit C. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell 2009; 36:365 - 78; http://dx.doi.org/10.1016/j.molcel.2009.09.032; PMID: 19917246
   PubMed Web of Science ®Google Scholar
• Dumontet C, Landi S, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S, et al. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplant 2010; 45:1316 - 24; http://dx.doi.org/10.1038/bmt.2009.335; PMID: 19966851
   PubMed Web of Science ®Google Scholar
• Ushie C, Saitoh T, Iwasaki A, Moriyama N, Murakami H.. The polymorphisms of base excision repair genes influence the prognosis of multiple myeloma. Blood ASH meeting abstracts 2012; 120
   Google Scholar
• Yang Z-Z, Chen X-H, Wang D. Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector. Clin Lymphoma Myeloma 2007; 7:296 - 304; http://dx.doi.org/10.3816/CLM.2007.n.006; PMID: 17324338
   PubMedGoogle Scholar
• de Larrea CF, Navarro A, Tovar N, Pedrosa F, Díaz T, Cibeira MAT, et al. Impact of single nucleotide polymorphisms in genes involved in DNA repair and drug metabolism on survival after autologous stem cell transplantation in patients with multiple myeloma. Blood ASH meeting abstracts 2012; 120:2934
   PubMed Web of Science ®Google Scholar
• Episkopou H, Kyrtopoulos SA, Sfikakis PP, Fousteri M, Dimopoulos MA, Mullenders LHF, Souliotis VL. Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. Cancer Res 2009; 69:4424 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-08-3489; PMID: 19417135
   PubMed Web of Science ®Google Scholar
• Martin P, Santón A, García-Cosio M, Bellas C. hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Mod Pathol 2006; 19:914 - 21; http://dx.doi.org/10.1038/modpathol.3800590; PMID: 16607377
   PubMed Web of Science ®Google Scholar
• Kotoula V, Hytiroglou P, Kaloutsi V, Barbanis S, Kouidou S, Papadimitriou CS. Mismatch repair gene expression in malignant lymphoproliferative disorders of B-cell origin. Leuk Lymphoma 2002; 43:393 - 9; http://dx.doi.org/10.1080/10428190290006215; PMID: 11999575
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012; 120:1077 - 86; http://dx.doi.org/10.1182/blood-2012-03-412981; PMID: 22573403
   PubMed Web of Science ®Google Scholar
• Osborne MR, Wilman DE, Lawley PD. Alkylation of DNA by the nitrogen mustard bis(2-chloroethyl)methylamine. Chem Res Toxicol 1995; 8:316 - 20; http://dx.doi.org/10.1021/tx00044a018; PMID: 7766817
   PubMed Web of Science ®Google Scholar
• Muniandy PA, Liu J, Majumdar A, Liu S-T, Seidman MM. DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol 2010; 45:23 - 49; http://dx.doi.org/10.3109/10409230903501819; PMID: 20039786
   PubMed Web of Science ®Google Scholar
• Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002; 100:224 - 9; http://dx.doi.org/10.1182/blood.V100.1.224; PMID: 12070031
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48 - 58; http://dx.doi.org/10.1038/nrc706; PMID: 11902585
   PubMed Web of Science ®Google Scholar
• Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003; 21:4239 - 47; http://dx.doi.org/10.1200/JCO.2003.06.001; PMID: 14615454
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfikakis PP. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica 2007; 92:1505 - 12; http://dx.doi.org/10.3324/haematol.11435; PMID: 18024399
   PubMed Web of Science ®Google Scholar
• Vangsted A, Gimsing P, Klausen TW, Nexø BA, Wallin H, Andersen P, Hokland P, Lillevang ST, Vogel U. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007; 120:1036 - 45; http://dx.doi.org/10.1002/ijc.22411; PMID: 17131345
   PubMed Web of Science ®Google Scholar
• Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005; 106:698 - 705; http://dx.doi.org/10.1182/blood-2004-11-4286; PMID: 15802532
   PubMed Web of Science ®Google Scholar
• Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009; 69:9367 - 75; http://dx.doi.org/10.1158/0008-5472.CAN-09-2616; PMID: 19934314
   PubMed Web of Science ®Google Scholar
• Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101:1053 - 62; http://dx.doi.org/10.1182/blood-2002-05-1320; PMID: 12393461
   PubMed Web of Science ®Google Scholar
• Xiao H, Xiao Q, Zhang K, Zuo X, Shrestha UK. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol 2010; 89:399 - 404; http://dx.doi.org/10.1007/s00277-009-0831-6; PMID: 19756599
   PubMed Web of Science ®Google Scholar
• Pan Y, Gao Y, Chen L, Gao G, Dong H, Yang Y, Dong B, Chen X. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res 2011; 17:3248 - 58; http://dx.doi.org/10.1158/1078-0432.CCR-10-0890; PMID: 21288924
   PubMed Web of Science ®Google Scholar
• Katayama M, Kawaguchi T, Berger MS, Pieper RO. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007; 14:548 - 58; http://dx.doi.org/10.1038/sj.cdd.4402030; PMID: 16946731
   PubMed Web of Science ®Google Scholar
• Couvé S, Macé-Aimé G, Rosselli F, Saparbaev MK. The human oxidative DNA glycosylase NEIL1 excises psoralen-induced interstrand DNA cross-links in a three-stranded DNA structure. J Biol Chem 2009; 284:11963 - 70; http://dx.doi.org/10.1074/jbc.M900746200; PMID: 19258314
   PubMed Web of Science ®Google Scholar
• McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM 3rd. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res 2009; 7:897 - 906; http://dx.doi.org/10.1158/1541-7786.MCR-08-0519; PMID: 19470598
   PubMed Web of Science ®Google Scholar
• Sousa MML, Zub KA, Aas PA, Hanssen-Bauer A, Demirovic A, Sarno A, Tian E, Liabakk NB, Slupphaug G. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells. PLoS One 2013; 8:e55493; http://dx.doi.org/10.1371/journal.pone.0055493; PMID: 23405159
   PubMedGoogle Scholar
• Crawford LJA, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TCM, Irvine AE. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006; 66:6379 - 86; http://dx.doi.org/10.1158/0008-5472.CAN-06-0605; PMID: 16778216
   PubMed Web of Science ®Google Scholar
• Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2011; 2:209 - 21; PMID: 21444945
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006; 46:189 - 213; http://dx.doi.org/10.1146/annurev.pharmtox.46.120604.141300; PMID: 16402903
   PubMed Web of Science ®Google Scholar
• Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 2007; 67:7395 - 405; http://dx.doi.org/10.1158/0008-5472.CAN-07-1015; PMID: 17671210
   PubMed Web of Science ®Google Scholar
• Murakawa Y, Sonoda E, Barber LJ, Zeng W, Yokomori K, Kimura H, Niimi A, Lehmann A, Zhao GY, Hochegger H, et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 2007; 67:8536 - 43; http://dx.doi.org/10.1158/0008-5472.CAN-07-1166; PMID: 17875693
   PubMed Web of Science ®Google Scholar
• Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, Tassone P, Mansoor A, Stewart DA, et al. Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011; 118:6368 - 79; http://dx.doi.org/10.1182/blood-2011-06-363911; PMID: 21917757
   PubMed Web of Science ®Google Scholar
• Roussel M, Moreau P, Huynh A, Mary J-Y, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pégourié B, et al, Intergroupe Francophone du Myélome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115:32 - 7; http://dx.doi.org/10.1182/blood-2009-06-229658; PMID: 19884643
   PubMed Web of Science ®Google Scholar
• Steele JM. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma. J Oncol Pharm Pract 2013; 19:348 - 54; http://dx.doi.org/10.1177/1078155212470388; PMID: 23292972
   PubMedGoogle Scholar
• Wang Q-E, Wani MA, Chen J, Zhu Q, Wani G, El-Mahdy MA, Wani AA. Cellular ubiquitination and proteasomal functions positively modulate mammalian nucleotide excision repair. Mol Carcinog 2005; 42:53 - 64; http://dx.doi.org/10.1002/mc.20065; PMID: 15547920
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327:1345 - 50; http://dx.doi.org/10.1126/science.1177319; PMID: 20223979
   PubMed Web of Science ®Google Scholar
• Zhu Y-X, Braggio E, Shi C-X, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118:4771 - 9; http://dx.doi.org/10.1182/blood-2011-05-356063; PMID: 21860026
   PubMed Web of Science ®Google Scholar
• Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 1992; 79:213 - 22; PMID: 1728309
   PubMed Web of Science ®Google Scholar
• Nojima M, Maruyama R, Yasui H, Suzuki H, Maruyama Y, Tarasawa I, Sasaki Y, Asaoku H, Sakai H, Hayashi T, et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res 2009; 15:4356 - 64; http://dx.doi.org/10.1158/1078-0432.CCR-08-3336; PMID: 19549772
   PubMed Web of Science ®Google Scholar
• Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 2003; 102:3379 - 86; http://dx.doi.org/10.1182/blood-2003-05-1417; PMID: 12855565
   PubMed Web of Science ®Google Scholar
• Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103:3148 - 57; http://dx.doi.org/10.1182/blood-2003-06-1984; PMID: 15070697
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Anderson KC. Bruton’s tyrosine kinase: oncotarget in myeloma. Oncotarget 2012; 3:913 - 4; PMID: 22989914
   PubMed Web of Science ®Google Scholar
• Cibeira MT, de Larrea CF, Navarro A, Díaz T, Fuster D, Tovar N, Rosiñol L, Monzó M, Bladé J. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leuk Res 2011; 35:1178 - 83; http://dx.doi.org/10.1016/j.leukres.2011.02.009; PMID: 21435719
   PubMed Web of Science ®Google Scholar
• Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD Jr.. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res 2008; 14:4821 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-4568; PMID: 18676754
   PubMed Web of Science ®Google Scholar
• Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ. Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell Cycle 2012; 11:2248 - 52; http://dx.doi.org/10.4161/cc.20343; PMID: 22617388
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481:287 - 94; http://dx.doi.org/10.1038/nature10760; PMID: 22258607
   PubMed Web of Science ®Google Scholar
• Smith J, Tho LM, Xu N, Gillespie DA. Chapter 3 - The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer. 1st ed. Elsevier Inc; 2010.
   Google Scholar
• Pei X-Y, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood 2011; 118:5189 - 200; http://dx.doi.org/10.1182/blood-2011-02-339432; PMID: 21911831
   PubMed Web of Science ®Google Scholar
• Smith J, Tho LM, Xu N, Gillespie DA. Chapter 3 - The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer. 1st ed. Elsevier Inc; 2010.
   Google Scholar
• Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD, Schwartz GK. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther 2012; 11:1781 - 8; http://dx.doi.org/10.1158/1535-7163.MCT-11-0949; PMID: 22653969
   PubMed Web of Science ®Google Scholar
• Caraux A, Vincent L, Bouhya S, Quittet P, Moreaux J, Requirand G, Veyrune JL, Olivier G, Cartron G, Rossi JF, et al. Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?. Oncotarget 2012; 3:1335 - 47; PMID: 23154454
   PubMed Web of Science ®Google Scholar